Anti-CD123 CAR-T

Anti-CD123 CAR-T is a form of chimeric antigen receptor (CAR) T cell therapy in which a patient's own (autologous) or donor-derived T cells are genetically engineered to express a synthetic receptor targeting CD123, the interleukin-3 receptor subunit alpha. CD123 is overexpressed on leukemic stem and progenitor cells in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), but has limited expression on normal hematopoietic stem cells. The engineered T cells recognize and kill malignant cells expressing CD123 through cytotoxic activity. Various constructs have been developed using different co-stimulatory domains such as 4-1BB or OX40 to enhance persistence and efficacy. Anti-CD123 CAR-T therapies are being investigated primarily for relapsed/refractory AML and high-risk MDS[1][2][3][4][5]. Developers include academic groups as well as companies such as Nanjing Legend Biotech[8].

Other names

CD123 chimeric antigen receptor T-cell therapyCD-123 chimeric antigen receptor T-cell therapyCD 123 chimeric antigen receptor T-cell therapy